My Treatment Approach: Optimizing Care for Relapsed / Refractory Multiple Myeloma: Translating Evidence to Clinical Practice

Robert Z. Orlowski, MD, PhD, and Jonathan Kaufman, MD, Leading experts in relapsed/refractory multiple myeloma, explore evolving treatment landscapes, including CAR T-cell therapies, the role of selinexor, and optimized sequencing strategies, while addressing two complex clinical scenarios and providing key insights for community oncologists to enhance patient care.

EP. 1: Clinical Scenario I: 68-yr Old Man with Early Relapse MM

August 14th 2024

Key opinion leaders present a clinical patient scenario involving a 68-year-old male patient presenting with early relapse multiple myeloma.

EP. 2: Clinical Insights on Next Treatment Approach Steps

August 14th 2024

A panel of experts in relapsed/refractory multiple myeloma analyzes a patient case, detailing their clinical approach to optimize outcomes for a 68-year-old male presenting with early relapse multiple myeloma.

EP. 3: Real Life Clinical Practice Use of Selinexor: Dosing Strategies, Supportive Care, and Strategies to Incorporate into Novel Selinexor-Based Regimens

August 21st 2024

The key opinion leaders examine selinexor combinations and dosing strategies they currently employ, while also addressing how the frequency of treatment-related adverse events (TRAEs) associated with selinexor varies with lower dosing regimens in the context of managing early relapse multiple myeloma.

EP. 4: Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM

August 21st 2024

The panelists explore the evolution of treatment approaches for patients with relapsed/refractory multiple myeloma who have undergone 1-3 lines of therapy, with a particular focus on the implications of increased anti-CD38 monoclonal antibody usage in newly diagnosed or early relapse cases.

EP. 5: Overview of CAR T-cell Therapy Options in R/R MM

August 28th 2024

The experts examine the available CAR T-cell therapy options for relapsed/refractory multiple myeloma.

EP. 6: Expert Perspectives: Selinexor Role in the Changing Treatment Landscape in MM and Key Takeaways

August 28th 2024

The panel evaluates selinexor's current role in the treatment landscape for multiple myeloma and explores its potential future applications and evolving significance in therapeutic strategies.

EP. 7: Patient Profile: 53-Year-Old Man with Heavily Pre-Treated MM including T-cell Directed Therapy

September 4th 2024

The panel presents and analyzes a case study of a 53-year-old man with heavily pre-treated multiple myeloma, including chemotherapy – based therapy and prior T-cell directed therapy, to illustrate treatment considerations and challenges in advanced disease management.